/ADXN
ADXN Stock - Addex Therapeutics Ltd
Healthcare|BiotechnologyNASDAQ
$7.83+0.26%
+$0.02 (+0.26%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.36
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+283.1%upside
Target: $30.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADXN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.75 – $7.91
TARGET (TP)$30.00
STOP LOSS$7.20
RISK/REWARD1:35.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.10
52W High$12.05
52W Low$6.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $404,102 | $1.61M | $1.42M | $2.92M | $3.61M |
| Gross Profit | $404,102 | $1.61M | $1.42M | $2.92M | $3.61M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-2,755,233 | $-2,242,967 | $-10,540,901 | $-15,505,917 | $-12,243,274 |
| Net Income | $7.06M | $-10,556,227 | $-20,804,213 | $-15,351,914 | $-12,858,599 |
| Net Margin | 1746.0% | -654.5% | -1462.6% | -526.4% | -355.9% |
| EPS | $8.40 | $-16.80 | $-55.20 | $-54.00 | $-57.60 |
Company Overview
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$30
Average Target
↑ 283.1% Upside
Now
$30
Low
$30
Average
$30
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 31st 2024 | H.C. Wainwright | Upgrade | Buy | $30 |
Earnings History & Surprises
ADXNBeat Rate
18%
Last 17 quarters
Avg Surprise
-1925.5%
EPS vs Estimate
Beats / Misses
3/12
2 met exactly
Latest EPS
$-2.77
Q4 2025
EPS Surprise History
Q2 24
+225.0%
$5.00vs$-4.00
Q2 24
-210.3%
$-1.37vs$-0.44
Q3 24
-17600.0%
$-1.77vs$-0.01
Q4 24
-97.9%
$-2.77vs$-1.40
Q2 25
-13600.0%
$-1.37vs$-0.01
Q2 25
+68.8%
$-1.33vs$-4.26
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 6, 2026 | — | — | — | — |
Q4 2025 | Dec 4, 2025 | — | $-2.77 | — | — |
Q3 2025 | Sep 29, 2025 | — | $-2.91 | — | — |
Q2 2025 | Jun 20, 2025 | $-4.26 | $-1.33 | +68.8% | ✓ BEAT |
Q2 2025 | Apr 25, 2025 | $-0.01 | $-1.37 | -13600.0% | ✗ MISS |
Q4 2024 | Nov 22, 2024 | $-1.40 | $-2.77 | -97.9% | ✗ MISS |
Q3 2024 | Sep 30, 2024 | $-0.01 | $-1.77 | -17600.0% | ✗ MISS |
Q2 2024 | Jun 6, 2024 | $-0.44 | $-1.37 | -210.3% | ✗ MISS |
Q2 2024 | Apr 4, 2024 | $-4.00 | $5.00 | +225.0% | ✓ BEAT |
Q4 2023 | Nov 29, 2023 | $-4.00 | $-4.07 | -1.8% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.83 | $-5.00 | -506.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-1.03 | $-5.20 | -404.2% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-1.03 | $-5.00 | -384.8% | ✗ MISS |
Q4 2022 | Nov 11, 2022 | $-11.20 | $-11.20 | 0.0% | = MET |
Q3 2022 | Aug 18, 2022 | $-11.20 | $-23.60 | -110.7% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-10.40 | $-19.40 | -86.5% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-13.20 | $-16.60 | -25.8% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-14.40 | $-14.40 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $-13.00 | $-15.40 | -18.5% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-13.00 | $-10.60 | +18.5% | ✓ BEAT |
Latest News
Addex Therapeutics Amends At The Market Offering Agreement With H.C. Wainwright & Co. For ADSs Up To $3.3M
➖ NeutralBenzinga•Dec 11, 2025, 07:53 AM
Addex Therapeutics Files Prospectus To Offer And Sell Ads For Up To $3.3M From Time To Time
➖ NeutralBenzinga•Dec 10, 2025, 09:26 PM
Addex Therapeutics Q3 EPS $(1.50) Up From $(2.77) YoY, Sales $62.500K Down From $68.161K YoY
➖ NeutralBenzinga•Dec 4, 2025, 07:57 AM
Addex Therapeutics Files For Stock Shelf Of Up To $150M
➖ NeutralBenzinga•Nov 19, 2025, 09:03 PM
Addex Boosts Capital Structure By Issuing 34.3M New Shares To Subsidiary Addex Pharma S.A. For Treasury Purposes
➖ NeutralBenzinga•Oct 29, 2025, 06:15 AM•Also:
Addex Therapeutics Q2 EPS $(2.90) Down From $10.61 YoY
📉 NegativeBenzinga•Sep 30, 2025, 05:22 AM
J&J hands epilepsy candidate to Addex ending decades-long partnership
📉 NegativeSeeking Alpha•Apr 17, 2025, 05:30 PM•Also:
Frequently Asked Questions about ADXN
What is ADXN's current stock price?
Addex Therapeutics Ltd (ADXN) is currently trading at $7.83 per share. The stock has moved +0.26% today.
What is the analyst price target for ADXN?
The average analyst price target for ADXN is $30.00, based on 1 analyst.
What sector is Addex Therapeutics Ltd in?
Addex Therapeutics Ltd operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ADXN's market cap?
Addex Therapeutics Ltd has a market capitalization of $0.01 billion, making it a small-cap company.
Does ADXN pay dividends?
No, Addex Therapeutics Ltd does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
BCLI
Brainstorm Cell Therapeutics Inc.
$0.56
Mkt Cap: $0.0B
CDIO
Cardio Diagnostics Holdings, Inc.
$3.23
Mkt Cap: $0.0B
IBO
Impact BioMedical Inc.
$0.65
Mkt Cap: $0.0B
MTNB
Matinas BioPharma Holdings, Inc.
$0.73
Mkt Cap: $0.0B
NBY
NovaBay Pharmaceuticals, Inc.
$5.30
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
RADX
Radiopharm Theranostics Limited
$5.19
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
Explore stocks similar to ADXN for comparison